<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088473</url>
  </required_header>
  <id_info>
    <org_study_id>21Neuro01</org_study_id>
    <nct_id>NCT05088473</nct_id>
  </id_info>
  <brief_title>Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases</brief_title>
  <official_title>Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous studies have shown the diagnostic interest of cerebrospinal fluid kappa free light&#xD;
      chains and kappa index in multiple sclerosis. However, large cohort studies are lacking and&#xD;
      little is known about the correlation between kappa and lambda indexes and multiple sclerosis&#xD;
      evidence disease activity. Therefore, this study plan to validate the kappa and lambda free&#xD;
      light chains and indexes as diagnostic biomarker in multiple sclerosis and to correlate the&#xD;
      concentration of kappa and lambda free light chains with clinical and radiological activity&#xD;
      in a large cohort of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Actual">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of cerebrospinal fluid (CSF) and serum kappa and lambda free light chains (KFLC and LFLC)</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of cerebrospinal fluid (CSF) and serum KFLC and LFLC by a turbilimetric analyzer (data in mg/L)&#xD;
Quantification of QKFLC and QLFLC (CSF FLC/serum FLC) in each group of patients&#xD;
Compare median of QKFLC and QLFLC between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of cerebrospinal fluid (CSF) and serum albumin</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of cerebrospinal fluid (CSF) and serum albumin by the same turbilimetric analyzer (data in mg/L)&#xD;
Quantification of albumin quotient (AQ) (CSF albumin/serum albumin) in each group of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the diagnostic performances of KFLC and LFLC intrathecal synthesis biomarkers (K/L FLC index and K/L FLC intrathecal fraction (IF)) for multiple sclerosis</measure>
    <time_frame>1 day</time_frame>
    <description>Calculation of KFLC intrathecal synthesis biomarkers:&#xD;
KFLC index = (CSF KFLC/serum KFLC) / AQ&#xD;
KFLC IF = (KFLC(loc)/CSF KFLC) x 100 with:&#xD;
KFLC(loc) = ((CSF KFLC/serum KFLC) / Qk(lim)) x serum KFLC and Qk(lim) = 3.27 x (AQ^2 + 33)^0.5 - 8.2&#xD;
Calculation of LFLC intrathecal synthesis biomarkers:&#xD;
LFLC index = (CSF LFLC/serum LFLC) / AQ)&#xD;
LFLC IF = (LFLC(loc)/CSF LFLC) x 100 with:&#xD;
LFLC(loc) = ((CSF LFLC/serum LFLC) / Ql(lim)) x serum LFLC and Ql(lim) = 2.1138 x AQ^0.865&#xD;
Determination of diagnostic performances by ROC curve analysis and best cut-off values with the Younden index to calculate sensitivity, specificity and predictive values for MS diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of diagnostic performances of K/L FLC intrathecal synthesis biomarkers to oligoclonal bands (OCB) for multiple sclerosis</measure>
    <time_frame>1 day</time_frame>
    <description>Identification of OCB status for each patient&#xD;
Calculation of diagnostic performances of OCB (sensitivity, specificity and predictive values) for MS diagnostic&#xD;
Comparison of diagnostic performances (sensitivity, specificity and predictive values) of OCB and K/L FLC intrathecal synthesis biomarkers for multiple sclerosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical data that can alter KFLC and LFLC values</measure>
    <time_frame>1 day</time_frame>
    <description>Identification of data that can be independtly associated with high or low CSF KFLC or LFLC values as potential bias in K/L FLC intrathecal synthesis biomarkers interpretation:&#xD;
Gender&#xD;
Age&#xD;
Type of clinical demyelinating event (i.e. myelitis, optic neuritis...)&#xD;
Immune modifying drug treatment ongoing during sampling&#xD;
Underlying disease activity (measured by the presence of subacute clinical symptoms ongoing at sampling or gadolinium enhanced lesions within the last MRI status)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1500</enrollment>
  <condition>Central Nervous System Diseases</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mutliple sclerosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CIS/RIS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Other CNS inflammatory diseases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non inflammatory CNS diseases</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological collection</intervention_name>
    <description>Collection of cerebrospinal fluid kappa and lambda free light chains and indexes</description>
    <arm_group_label>CIS/RIS</arm_group_label>
    <arm_group_label>Mutliple sclerosis</arm_group_label>
    <arm_group_label>Non inflammatory CNS diseases</arm_group_label>
    <arm_group_label>Other CNS inflammatory diseases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with symptoms evocative of CNS disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with symptoms evocative of CNS involvement for who serum and&#xD;
             cerebrospinal fluid kappa free light chains and kappa index are available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infectious CNS disease&#xD;
&#xD;
          -  Tumor CNS disease&#xD;
&#xD;
          -  Active CNS bleeding&#xD;
&#xD;
          -  Monoclonal gammapathy&#xD;
&#xD;
          -  Severe chronic renal failure (glomerular filtration rate &lt;30 ml/mn)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional et Universaitaire de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>kappa free light chains</keyword>
  <keyword>lambda free light chains</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

